Rakesh Jhunjhunwala, LIC hiked stake in this pharma company in Q2
Total holdings of mutual fund houses in the company also increased to 12.58 per cent from 11.94 per cent on a quarter-on-quarter basis, data available with BSE showed on Tuesday.
IT looks good, but pharma is a structural story
In the near term, even the cyclical part of the economy will pick up. Digital and manufacturing are more medium to longer-term drivers. There is a two-three year visibility there, says Rana B Gupta.
Bullish on pharma? 4 big challenges ahead
Chinese manufacturers have increased the cost of key starting materials (KSMs), or intermediates, by up to 20%, escalating the input cost for Indian pharma companies.
Sensex, Nifty start on cautious note; IT, pharma stocks rally
Equity benchmarks Sensex and Nifty opened on a cautious note on Monday amid lack of directional cues from global and domestic markets. The 3...
Piramal Pharma stake sale to provide war chest for acquisitions & growth
We had planned to close the deal by the end of the year and we managed to finish it by the end of September, says Nandini Piramal.
Big boys of India's pharmaceutical industry may reshape Indian e-pharma
India's $20-billion pharmaceutical industry is set for a shakeup as giants Reliance Retail and Amazon chart plans to enter the e-pharmacy space, a move that experts said would take the country closer to a transformed drug market.
Pharmaceutical industry at forefront of battle against COVID-19: Sun Pharma chairman
"Sun Pharma has ensured adequate supplies of medicines to its customers across the world despite the supply chain disruptions and the lockdown restrictions in various countries," he added. Changes at manufacturing facilities have been made to ensure productivity, as well as adherence to all safety and hygiene protocols.
Buy Sun Pharma, target price Rs 554: ICICI Securities
Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 123301.82 Crore) operating in Pharmaceuticals sector.
Betting on pharma? Build a basket of these stocks
We have probably seen 20% of the rerating in pharma but it will take about one, one and a half years for the entire thing to play out, says Sudip Bandyopadhyay.
Sensex reclaims 39,000, ends 288 points higher; Nifty tops 11,500, pharma and banking stocks shine
Equity indices found firmer ground on Tuesday as investors poured money into banking and finance counters amid a positive trend in global ma...
Pharma sector to remain a market favourite due to earnings visibility, say analysts
The sector will remain a market favourite due to earnings visibility, which does not exist for most sectors currently because of the pandemic. Analysts said there is potential for earnings to double in the next five years.
Stock market update: Pharma stocks rise; Sun Pharma gains 2%
The Nifty Pharma index was trading 0.76 per cent up at 11628.05.
Granules India surges 10% as three PE firms look to pick controlling stake
A media report said that Blackstone, KKR and Bain Capital have submitted non-binding bids for the proposed transaction and investment bank Kotak Mahindra Capital has been engaged by the promoters of Granules India to look for buyers.
Pharma unlikely to see steep rally ahead, better to exit: Anand Tandon
'SC not an expert, must leave moratorium decision on RBI'
View: India’s pharma industry needs innovation-promoting and smart regulation to up its game
The Indian pharmaceutical industry is a fine example of how such investment in R&D, combined with supportive public policy, has created global players. However, the pharma, biology and healthcare industry needs a public policy framework that will support private investment in R&D and innovation to maintain India’s pre-eminent position in this sector.